Immunobiology of the Macrophage presents an account of the state of knowledge of the immunobiology of the macrophage. The book's contributors—immunologists of diverse scientific and geographic backgrounds—have been encouraged to give personal accounts of developments in their special fields of interest as well as critical surveys of the backgrounds leading to these developments. The book begins with a study on the functions of macrophages in the initiation and regulation of antibody responses in vitro. This is followed by separate chapters on topics such as the role of macrophages in making antigen more immunogenic and less tolerogenic; functional distinctions between macrophages at different sites; and the role of the macrophage in antigen recognition by T lymphocytes. Subsequent chapters examine interactions between macrophages and lymphocytes in the production of interferon and other mediators of cellular immunity; macrophage cell lines and their uses in immunobiology; and cytotoxic macrophages in allograft rejection.

Macrophages are core components of the innate immune system. Once activated, they may have either pro- or anti-inflammatory effects that include pathogen killing, safe disposal of apoptotic cells or tissue renewal. The activation state of macrophages is conceptualized by the so-called M1/M2 model of polarization. M2 macrophages are not simply antagonists of M1 macrophages; rather, they represent a network of tissue resident macrophages with roles in tissue development and organ homeostasis. M2 macrophages govern functions at the interfaces of immunity, tissue development and turnover, metabolism, and endocrine signaling. Dysfunction in M2 macrophages can ruin the healthy interplay between the immune system and metabolic processes, and lead to diseases such as insulin resistance, metabolic syndrome, and type 1 and 2 diabetes mellitus. Furthermore, M2 macrophages are essential for healthy tissue development and immunological self-tolerance. Worryingly, these functions of M2 macrophages can also be disrupted, resulting in tumor growth and autoimmunity. This book comprehensively discusses the biology of M2 macrophages, summarizes the current state of knowledge, and highlights key questions that remain unanswered.

The Macrophage, second edition provides a unique, comprehensive review of the current scientific knowledge of the multifaceted role of this important and intriguing cell in health and disease. In 16 chapters, written by experts in the field, it covers the basic biology and diverse functions of macrophages in specific diseases and the complex interactions between macrophages and other cells. Ranging from their role in the defence against pathogens, their role as hosts for pathogens (including HIV), their complex roles in diseases such as arthritis and cancer, and their potential for use in novel gene therapy approaches to disease treatment, the book gives an up to the minute account of active macrophage research.

Session I. Role of tumor macrophages in Vivo / William Regelson -- Session II. Macrophage function and interaction / Dolph O. Adams -- Session III. Mechanisms of macrophage mediated cytotoxicity / D. Bernard Amos -- The macrophage as a tumoricidal effector cell: a review in Vivo and In Vitro, Studies on the mechanism of the activated macrophage nonspecific cytotoxic reaction / John B. Hibbs, Jr. -- Morphologic aspects of tumor cell cytotoxicity by effector cells of the macrophage-histocyte compartment: in Vitro and in Vivo studies in BCG-mediated tumor regression / M.G. Hanna [and others] -- Session IV. Functional expression of macrophages and neoplasia / Osias Stutman -- The employment of Glucan and glucan activated macrophages in the enhancement of host resistance to malignancies in experimental animals / N.R. DiLuzio [and others] -- Session V. Stimulation of macrophage function and applied therapy / Ole A. Holtermann -- The in Vivo destruction of human tumor by glucan activated macr ...

The Janeway's Immunobiology CD-ROM, Immunobiology Interactive, is included with each book, and can be purchased separately. It contains animations and videos with voiceover narration, as well as the figures from the text for presentation purposes.

The second edition of Avian Immunology provides an up-to-date overview of the current knowledge of avian immunology. From the ontogeny of the avian immune system to practical application in vaccinology, the book encompasses all aspects of innate and adaptive immunity in chickens. In addition, chapters are devoted to the immunology of other commercially important species such as turkeys and ducks, and to ecoimmunology summarizing the knowledge of immune responses in free-living birds often in relation to reproductive success. The book contains a detailed description of the avian innate immune system, encompassing the mucosal, enteric, respiratory and reproductive systems. The diseases and disorders it covers include immunodepressive diseases and immune evasion, autoimmune diseases, and tumors of the immune system. Practical aspects of vaccination are examined as well. Extensive appendices summarize resources for scientists including cell lines, inbred chicken lines, cytokines, chemokines, and monoclonal antibodies. The world-wide importance of poultry protein for the human diet, as well as the threat of avian influenza pandemics like H5N1 and heavy reliance on vaccination to protect commercial flocks makes this book a vital resource. This book provides crucial information not only for poultry health professionals and avian biologists, but also for comparative and veterinary immunologists, graduate students and veterinary students with an interest in avian immunology. - With contributions from 33 of the foremost international experts in the field, this book provides the most up-to-date review of avian immunology so far - Contains a detailed description of the avian innate immune system reviewing constitutive barriers, chemical and cellular responses; it includes a comprehensive review of avian Toll-like receptors - Contains a wide-ranging review of the "ecoimmunology" of free-living avian species, as applied to studies of population dynamics, and reviews methods and resources available for carrying out such research

Immune Rebalancing: The Future of Immunosuppression summarizes the most promising perspectives of immunopharmacology, in particular in the area of immunosuppression by considering molecular pathways, personalized medicine, microbiome and nanomedicine. Modulation of immune responses for therapeutic purposes is a particularly relevant area, given the central role of anomalous immunity in diseases. These diseases vary from the most typically immune-related syndromes (autoimmune diseases, allergy and asthma, immunodeficiencies) to those in which altered immunity and inflammation define the pathological outcomes (chronic infections, tumours, chronic inflammatory and degenerative diseases, metabolic disorders, etc. - Visits immunosuppression from a modern point of view of signalling mechanisms at the light of the current knowledge of signalling mechanisms and regulatory networks allows the reader to formulate new ideas and concepts on how to use immunosuppression the therapeutic purposes - Encourages researchers to engage into exploring the field of pharmacological modulation of immune responses in depth, and with the new knowledge and tools available, designs more effective therapeutic strategies to autoimmune and inflammatory diseases, cancer, degenerative diseases and infections - Examines the link between molecular pathways associated to immune-suppression and the new immunopharmacology approaches - Provides information on the new strategies for drug development in this field - Considers the role of microbes in the development of the mammalian immune system and immune responses, which will widen the reader's strategy for addressing therapeutic immune modulations

During the past decade, the rapid growth of molecular and cellular knowledge of macrophages, as a specialized host defense and homeostatic system, has begun to offer attractive targets for therapeutic intervention. Macrophages play a central role in a wide range of disease processes, from genetically determined lysosomal storage diseases, to acute sepsis, chronic inflammation and repair, tissue injury and cell death. Under- or overactivity of macrophage clearance, immune effector functions and responses to metabolic abnormalities contribute to common disorders such as autoimmunity, atherosclerosis, Alzheimer’s disease and major infections including AIDS and Tuberculosis. Whilst the goals of therapeutic intervention based on improved understanding of macrophage functions and their contribution to pathogenesis may seem self evident, there are considerable difficulties in producing useful new agents. The present volume covers a range of subjects and provides opportunities for a more focused macrophage-targeted approach. The individual chapters review selected topics briefly, to place cellular processes and molecular targets in perspective. Overall, the volume should provide a broad sample of the state of the art. Useful reviews and references in the literature are cited within individual chapters.

The mononuclear phagocyte system (MPS) comprises dendritic cells (DCs), monocytes and macrophages (MØs) that together play crucial roles in tissue immunity and homeostasis, but also contribute to a broad spectrum of pathologies. They are thus attractive therapeutic targets for immune therapy. However, the distinction between DCs, monocytes and MØ subpopulations has been a matter of controversy and the current nomenclature has been a confounding factor. DCs are remarkably heterogeneous and consist of multiple subsets traditionally defined by their expression of various surface markers. While markers are important to define various populations of the MPS, they do not specifically define the intrinsic nature of a cell population and do not always segregate a bona fide cell type of relative homogeneity. Markers are redundant, or simply define distinct activation states within one subset rather than independent subpopulations. One example are the steady-state CD11b+ DCs which are often not distinguished from monocytes, monocyte-derived cells, and macrophages due to their overlapping phenotype. Lastly, monocyte fate during inflammation results in cells bearing the phenotypic and functional features of both DCs and MØs significantly adding to the confusion. In fact, depending on the context of the study and the focus of the laboratory, a monocyte-derived cell will be either be called "monocyte-derived DCs" or "macrophages". Because the names we give to cells are often associated with a functional connotation, this is much more than simple semantics. The "name" we give to a population fundamentally changes the perception of its biology and can impact on research design and interpretation. Recent evidence in the ontogeny and transcriptional regulation of DCs and MØs, combined with the identification of DC- and MØ-specific markers has dramatically changed our understanding of their interrelationship in the steady state and inflammation. In steady state, DCs are constantly replaced by circulating blood precursors that arise from committed progenitors in the bone marrow. Similarly, some MØ populations are also constantly replaced by circulating blood monocytes. However, others tissue MØs are derived from embryonic precursors, are seeded before birth and maintain themselves in adults by self-renewal. In inflammation, such differentiation pathways are fundamentally changed and unique monocyte-derived inflammatory cells are generated. Current DC, monocyte and MØ nomenclature does not take into account these new developments and as a consequence is quite confusing. We believe that the field is in need of a fresh view on this topic as well as an upfront debate on DC and MØ nomenclature. Our aim is to bring expert junior and senior scientists to revisit this topic in light of these recent developments. This Research Topic will cover all aspects of DC, monocyte and MØ biology including development, transcriptional regulation, functional specializations, in lymphoid and non-lymphoid tissues, and in both human and mouse models. Given the central position of DCs, monocytes and MØs in tissue homeostasis, immunity and disease, this topic should be of interest to a large spectrum of the biomedical community.